Finance

Lists
MBX:NASDAQ
MBX Biosciences Inc
$62.91
-0.13%
(-0.080) 1D
$62.91
0.00% (0.00)
After hours
Closed: Sep 9, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MBX...
Open
$63.29
High
$64.04
Low
$61.28
Mkt. cap
3.03B
Avg. vol.
433.00K
Volume
315.69K
52-wk high
$72.64
52-wk low
$9.63
EPS
-$2.41
Shares outstanding
48.16M
No. of employees
63
Open
$63.29
High
$64.04
Low
$61.28
Mkt. cap
3.03B
Avg. vol.
433.00K
Volume
315.69K
52-wk high
$72.64
52-wk low
$9.63
EPS
-$2.41
Shares outstanding
48.16M
No. of employees
63
News stories
From web sources and news partners
About MBX Biosciences Inc
CEO-
Employees63
Founded2018
HeadquartersCarmel, Indiana, United States
SectorPharmaceutical industry
Websitembxbio.com
Analyst ratings
Based on 9 analysts giving stock ratings to MBX in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for MBX in the last 3 months.
Highest
Current $62.91
$121.00 (+92.34%)
Average
$89.33 (+42.00%)
Lowest
$70.00 (+11.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jessica Fye
J.P. Morgan
Buy
Initiated
$88.00
+39.9%
08/21/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$70.00
+11.3%
08/11/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
$88.00
+39.9%
08/10/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$91.00
+44.7%
08/07/2026
Eliana Merle
Barclays
Buy
Maintained
$88.00
+39.9%
08/07/2026
Patrick Dolezal
LifeSci Capital
Buy
Reiterated
$121.00
+92.3%
08/08/2026
Michael Yee
UBS
Buy
Reiterated
$90.00
+43.1%
07/24/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$88.00
+39.9%
07/14/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$80.00
+27.2%
06/15/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$86.00
+36.7%
05/12/2026
Patrick Scholes
Truist Financial
Buy
Maintained
$70.00
+11.3%
05/11/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/07/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.78 / -$0.59
-33.18%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
19.27M
19.46M
18.47M
30.98M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.66M
6.34M
8.79M
9.95M
Operating expense
23.93M
25.80M
27.26M
40.93M
Total operating expenses
23.93M
25.80M
27.26M
40.93M
Operating income
-23.93M
-25.80M
-27.26M
-40.93M
Other non operating income
-
-
-
-
EBT including unusual items
-21.62M
-22.06M
-23.52M
-37.10M
EBT excluding unusual items
-21.62M
-25.67M
-24.10M
-37.10M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-21.62M
-22.06M
-23.52M
-37.10M
Net profit margin
-
-
-
-
Earnings per share
-0.63
-0.49
-0.51
-0.78
Interest and investment income
2.31M
122.00K
3.17M
3.84M
Interest expense
-
-
-
-
Net interest expenses
2.31M
122.00K
3.17M
3.84M
Depreciation and amortization charges
-
-
-
-
EBITDA
-23.88M
-25.74M
-27.20M
-40.85M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps